Jack A Tuszynski

Dr. Tuszynski obtained an M.Sc. with distinction in physics at the University of Poznan, Poland. In 1983 he was awarded a Ph.D. in physics at the University of Calgary, Canada. He is currently full professor at the Polytechnic University of Turin (Politecnico di Torino) in Italy. His employment experience includes being an assistant professor at Memorial University of Newfoundland and then being appointed as professor in the Department of Physics at the University of Alberta. Dr. Tuszynski also held visiting professor appointments at the University of Bielefeld, Germany, Nankai University, China, ENS Lyon, France, University of Leuven, Belgium, Universität Gießen, Germany, Universität Düsseldorf, Germany and Danish Technical University. He also worked as a research manager in a private R&D company in Brussels, Belgium, called Starlab. Between 2005 and 2020 Dr. Tuszynski held the prestigious endowed chair in experimental oncology at the University of Alberta. He holds 1 Brazilian and 7 US patents, has published over 650 refereed journal papers, 60 conference proceedings, 15 research monographs and 20 book chapters. His h-index according to Google scholar is 74. He has served on the editorial boards of 30 scientific journals and has been an Associate Editor for the Frontiers Collection of the Springer Verlag, Heidelberg. Dr. Tuszynski gave 200 invited talks at conferences and workshops on six continents. His record of graduate supervision includes over 20 PDFs, 32 PhDs and 53 M.Sc. students. He has been collaborating with and consulting for companies in the biotech and pharma area around the world, including Sinoveda (Canada), Telormedix (Switzerland), Novocure (Israel), Oncovista (San Antonio), CSTS (Canada), Autem Medical (Brazil), Vielight (Canada) and Zepter (Switzerland). He co-founded two University of Alberta spin-off companies: ProPhysis and Achlys. His research focuses on the use of high-performance computing in drug discovery and involves biomolecular modeling, virtual drug screening, bioinformatics and systems biology. As a result, one of the lead drugs he discovered computationally is now completing Phase I/II clinical trials for metastatic baldder cancer. Another drug is currently undergoing lead optimization for colorectal cancer. The 2023 book entitled “Quantum Body”, he co-authored presents a vision for the future of medicine inspired by modern physics.